Physician profile
Peter G Lapman
NPI 1568637858
$10,288.45
in general payments reported to CMS, 2019-2025
39 companies · $3,019 in 2025
The $3,019 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $677 · 2021: $1,205 · 2022: $1,453 · 2023: $1,261 · 2024: $1,381 · 2025: $3,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,660.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,362.06 | 2019-2025 | |
| Amgen INC. | $1,202.49 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $912.60 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $765.41 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $572.38 | 2019-2023 | |
| Pfizer INC. | $493.36 | 2019-2025 | |
| Boston Scientific Corporation | $484.88 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman |
| Abbott Laboratories | $482.27 | 2019-2024 | Jot Dx, Aveir |
| Alnylam Pharmaceuticals INC. | $449.91 | 2024-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $418.54 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $370.75 | 2019-2023 | Xarelto |
| Cvrx, INC. | $340.03 | 2021-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $335.44 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.21 | 2019-2025 | Jardiance |
| Heartflow, INC. | $289.78 | 2021-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.